LLS Seeks Blood Cancer Research Program with US Military

Testifying before a U.S. Senate Subcommittee on Defense Appropriations, George Dahlman, the senior vice president of public policy for the Leukemia & Lymphoma Society (LLS) requested the necessary funding to create a "stand-alone blood cancer research program" at the US Department of Defense (DOD).

Dahlman wants a 'collaborative public-private effort between the U.S. Military Cancer Institute, the LLS and a blue ribbon panel of scientific academicians,' according to the press release.

"A joint effort, tapping the expertise of both USMCI and LLS, represents a unique opportunity to identify valuable research opportunities and state-of-the-art technology that can address significant questions on the origins and diagnosis of blood cancers," according to Dahlman.

The LLS has good reason to seek a collaboration with the USMCI, since this institute possesses a treasure trove of electronic medical records, including serum and tissue specimens, from an estimated 9 million servicemen and women and their families. A strong link has been made between cancers such as chronic lymphocytic leukemia (CLL), multiple myeloma and a variety of other lymphomas, and those members of the US military serving in wars in Vietnam and the Gulf, making these records all the more valuable for epidemiologists and other researchers to study blood cancers.

But that's not the only reason for the request. Added Dahlman, "DOD research on blood cancers addresses the importance of preparing for civilian and military exposure to the weapons being developed by several hostile nations and to aid in the march to more effective treatment for all who suffer from these diseases."

Scary.


Source:
LLS Press Room

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap